ProKidney Corp. (PROK) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.84
↓-71% vs avg
5yr avg: 2.85
30Y Low0.3·High11.7
ROE
↑
-43.2%
↓+47% vs avg
5yr avg: -81.4%
30Y Low-300%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PROK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ProKidney Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $299M | $300M | $165M | $110M | $422M | $316M | — | — |
| Enterprise Value | $194M | $194M | $70M | $54M | $-65687015 | $296M | — | — |
| P/E Ratio → | -3.69 | — | — | — | — | — | — | — |
| P/S Ratio | 335.29 | 335.98 | 2177.35 | — | — | — | — | — |
| P/B Ratio | 0.84 | 1.00 | 0.41 | 0.28 | 0.84 | 11.73 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PROK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 217.76 | 915.72 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
PROK Profitability
Margins and return-on-capital ratios measuring operating efficiency
ProKidney Corp. earns an operating margin of -18477.8%. Operating margins have expanded from -241678.9% to -18477.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -43.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -540.8% | -540.8% | 100.0% | — | — | — | — | — |
| Operating Margin | -18477.8% | -18477.8% | -241678.9% | — | — | — | — | — |
| Net Profit Margin | -16977.8% | -16977.8% | -80507.9% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -43.2% | -43.2% | -15.4% | -7.9% | -40.6% | -299.9% | -207.8% | -501.3% |
| ROA | -39.0% | -39.0% | -14.2% | -7.6% | -38.7% | -193.5% | -147.3% | -406.1% |
| ROIC | -49.4% | -49.4% | -43.0% | -64.5% | -926.2% | -568.6% | -470.6% | -3365.5% |
| ROCE | -46.5% | -46.5% | -45.9% | -33.6% | -57.2% | -281.3% | -192.4% | -469.9% |
PROK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $109M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.05 | 0.16 | 0.07 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.24 | -0.14 | -0.97 | -0.71 | -0.31 | -0.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -41251.75 | -41251.75 | -20408.44 | -12626.83 | -711.66 | — | — | — |
Net cash position: cash ($109M) exceeds total debt ($3M)
PROK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ProKidney Corp.'s current ratio of 9.13x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.94x to 9.13x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.13 | 9.13 | 10.93 | 14.94 | 46.42 | 2.21 | 1.02 | 5.68 |
| Quick Ratio | 9.13 | 9.13 | 10.93 | 14.94 | 46.42 | 2.21 | 1.02 | 5.68 |
| Cash Ratio | 8.78 | 8.78 | 9.89 | 14.50 | 45.09 | 1.67 | 0.83 | 5.61 |
| Asset Turnover | — | 0.00 | 0.00 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 460.64 | 11752.04 | — | — | — | — | — |
PROK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ProKidney Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 8.6% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 8.6% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $134M | $98M | $62M | $62M | $32M | $187M | $79M |
Peer Comparison
Compare PROK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PROKYou | $299M | -3.7 | — | — | -540.8% | -18477.8% | -43.2% | -49.4% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 ALLO | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
 SANA | $918M | -3.0 | — | — | — | — | -99.2% | -86.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See PROK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PROK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PROK vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonPROK — Frequently Asked Questions
Quick answers to the most common questions about buying PROK stock.
What is ProKidney Corp.'s P/E ratio?
ProKidney Corp.'s current P/E ratio is -3.7x. This places it at the 50th percentile of its historical range.
What is ProKidney Corp.'s ROE?
ProKidney Corp.'s return on equity (ROE) is -43.2%. The historical average is -102.5%.
Is PROK stock overvalued?
Based on historical data, ProKidney Corp. is trading at a P/E of -3.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ProKidney Corp.'s profit margins?
ProKidney Corp. has -540.8% gross margin and -18477.8% operating margin.